Literature DB >> 16867998

Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team.

Jean-Ralph Zahar1, Christophe Rioux, Emmanuelle Girou, Anne Hulin, Colette Sauve, Alexandra Bernier-Combes, Christian Brun-Buisson, Philippe Lesprit.   

Abstract

OBJECTIVES: Many factors are involved in the appropriate use of aminoglycosides, such as modalities of administration, drug levels monitoring and duration of treatment. We assessed prospectively the impact of an antibiotic control team on the appropriateness of prescriptions.
METHODS: After a first observational audit assessing the appropriateness of prescriptions, and issuing updated recommendations, we performed an interventional audit, where an antibiotic control team provided counselling when prescriptions were considered inappropriate. Appropriateness of prescriptions, clinical outcomes of patients and medical costs were compared between the two periods.
RESULTS: One hundred consecutive prescriptions were analysed in each period, and 32% of prescriptions were modified by the control team. As compared with the observational period, prescriptions in the intervention period were more appropriate with regard to treatment duration (73% versus 56%, P = 0.01) and drug levels monitoring (61% versus 40%, P = 0.05), and the median treatment duration was shorter (4 versus 6 days, P = 0.0002). Independent factors associated with appropriate treatment duration were hospitalization in intensive care unit [adjusted odds ratio (aOR), 4.46; 95% confidence interval (CI), 1.60-12.46], polymicrobial infection (aOR, 3.97; 1.32-11.92) and antibiotic control team intervention (aOR, 2.49; 1.27-4.87). The intervention period was associated with lower rate of nephrotoxicity (15% versus 4%, P = 0.01) and lower direct medical costs (4,039.4 Euros per 100 persons treated).
CONCLUSIONS: Aminoglycoside use was frequently associated with excessive treatment duration and incorrect drug level monitoring. Reinforcing practice guidelines through direct counselling improved the appropriateness of prescriptions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16867998     DOI: 10.1093/jac/dkl288

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Section 3: Prevention and Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

Review 2.  Aminoglycoside-induced ototoxicity.

Authors:  Jerome A Leis; John A Rutka; Wayne L Gold
Journal:  CMAJ       Date:  2014-09-15       Impact factor: 8.262

3.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

Review 4.  The implications and management of septic acute kidney injury.

Authors:  Zaccaria Ricci; Andrea Polito; Angelo Polito; Claudio Ronco
Journal:  Nat Rev Nephrol       Date:  2011-03-01       Impact factor: 28.314

Review 5.  Clinical approach to the patient with AKI and sepsis.

Authors:  Mélanie Godin; Patrick Murray; Ravindra L Mehta
Journal:  Semin Nephrol       Date:  2015-01       Impact factor: 5.299

6.  Aminoglycoside use in a pediatric hospital: there is room for improvement-a before/after study.

Authors:  Mélanie Houot; Benoit Pilmis; Valérie Thepot-Seegers; Clémence Suard; Cyrielle Potier; Martine Postaire; Jean-Ralph Zahar
Journal:  Eur J Pediatr       Date:  2016-01-21       Impact factor: 3.183

Review 7.  Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.

Authors:  Alexandre Boyer; Didier Gruson; Stéphane Bouchet; Benjamin Clouzeau; Bui Hoang-Nam; Frédéric Vargas; Hilbert Gilles; Mathieu Molimard; Anne-Marie Rogues; Nicholas Moore
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

8.  Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units.

Authors:  João F P Oliveira; Carolina A Silva; Camila D Barbieri; Giselle M Oliveira; Dirce M T Zanetta; Emmanuel A Burdmann
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

9.  Risk of AKI with gentamicin as surgical prophylaxis.

Authors:  Samira Bell; Peter Davey; Dilip Nathwani; Charis Marwick; Thenmalar Vadiveloo; Jacqueline Sneddon; Andrea Patton; Marion Bennie; Stewart Fleming; Peter T Donnan
Journal:  J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 10.121

Review 10.  Antimicrobial stewardship: a review of prospective audit and feedback systems and an objective evaluation of outcomes.

Authors:  Gladys W Chung; Jia En Wu; Chay Leng Yeo; Douglas Chan; Li Yang Hsu
Journal:  Virulence       Date:  2013-01-09       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.